Moderna, Inc.: Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia , Presented at the 2023 ASGCT Annual Meeting
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacementTo date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging early